1. Home
  2. CTNM vs CIA Comparison

CTNM vs CIA Comparison

Compare CTNM & CIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • CIA
  • Stock Information
  • Founded
  • CTNM 2009
  • CIA 1969
  • Country
  • CTNM United States
  • CIA United States
  • Employees
  • CTNM N/A
  • CIA N/A
  • Industry
  • CTNM
  • CIA Life Insurance
  • Sector
  • CTNM
  • CIA Finance
  • Exchange
  • CTNM Nasdaq
  • CIA Nasdaq
  • Market Cap
  • CTNM 248.7M
  • CIA 261.8M
  • IPO Year
  • CTNM 2024
  • CIA N/A
  • Fundamental
  • Price
  • CTNM $12.40
  • CIA $5.59
  • Analyst Decision
  • CTNM Strong Buy
  • CIA
  • Analyst Count
  • CTNM 4
  • CIA 0
  • Target Price
  • CTNM $22.75
  • CIA N/A
  • AVG Volume (30 Days)
  • CTNM 246.0K
  • CIA 127.9K
  • Earning Date
  • CTNM 11-05-2025
  • CIA 11-06-2025
  • Dividend Yield
  • CTNM N/A
  • CIA N/A
  • EPS Growth
  • CTNM N/A
  • CIA N/A
  • EPS
  • CTNM N/A
  • CIA 0.22
  • Revenue
  • CTNM N/A
  • CIA $245,943,000.00
  • Revenue This Year
  • CTNM N/A
  • CIA $4.22
  • Revenue Next Year
  • CTNM N/A
  • CIA $4.46
  • P/E Ratio
  • CTNM N/A
  • CIA $25.35
  • Revenue Growth
  • CTNM N/A
  • CIA N/A
  • 52 Week Low
  • CTNM $3.35
  • CIA $2.90
  • 52 Week High
  • CTNM $20.30
  • CIA $5.95
  • Technical
  • Relative Strength Index (RSI)
  • CTNM 69.65
  • CIA 66.41
  • Support Level
  • CTNM $11.46
  • CIA $5.27
  • Resistance Level
  • CTNM $13.09
  • CIA $5.46
  • Average True Range (ATR)
  • CTNM 1.02
  • CIA 0.16
  • MACD
  • CTNM -0.07
  • CIA -0.02
  • Stochastic Oscillator
  • CTNM 74.89
  • CIA 88.71

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About CIA Citizens Inc. ($1.00 Par)

Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. The company operates in two business segments namely the Life Insurance segment and the Home Service Insurance segment. The company majority generates revenues from Life Insurance segment. Company operates in USA, Columbia, Taiwan, Venezuela, Ecuador, Argentina, and Others.

Share on Social Networks: